Causes & What We Know/November 4, 2026/3 min read

Beyond Insulin: How Alpha-Glucosidase Inhibitors May Help Some People with Type 1 Diabetes

A new review examines whether a class of medications that slow carbohydrate digestion could serve as a helpful addition to insulin therapy for people with Type 1 diabetes. The evidence shows modest benefits, but gastrointestinal side effects remain a challenge.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

Alpha-glucosidase inhibitors (AGIs) work by slowing how quickly your intestines break down and absorb carbohydrates, which can reduce blood sugar spikes after meals.
Research suggests AGIs may modestly lower HbA1c, improve post-meal glucose control, and potentially reduce insulin requirements when used alongside insulin therapy.
Gastrointestinal side effects like bloating and gas are common and often limit how long people can stick with AGI treatment.
AGIs may be most useful for people who experience significant blood sugar spikes after eating, consume high amounts of carbohydrates, or cannot use other adjunctive medications.
Newer medications like GLP-1 agonists and SGLT-2 inhibitors may offer broader benefits, but AGIs still have a potential role for select individuals.

What Type 1 Diabetes Is and Why Insulin Alone Isn't Always Enough

Type 1 diabetes is an autoimmune condition in which the body's immune system damages the insulin-producing beta cells in the pancreas. Without insulin, the body cannot properly manage blood sugar, and glucose metabolism breaks down—affecting not only carbohydrate control but also protein and fat metabolism.

Insulin therapy is the foundation of Type 1 diabetes treatment, but even with careful management, achieving stable blood sugar can be difficult. Many people struggle with hypoglycemia (dangerously low blood sugar), weight gain, and the limitations of how insulin works in the body. For these reasons, researchers have been exploring additional medications that work alongside insulin to improve blood sugar control.

How Alpha-Glucosidase Inhibitors Work

Alpha-glucosidase inhibitors (AGIs) take a different approach from insulin. Instead of directly providing the hormone your body lacks, AGIs slow the process by which your digestive system breaks down carbohydrates. By delaying carbohydrate absorption in the intestines, AGIs reduce the sharp rise in blood sugar that happens after eating—what doctors call postprandial glucose spikes.

Because AGIs work on digestion rather than on insulin production or action, they can be used as an addition to insulin therapy without requiring changes to insulin doses or timing.

What the Evidence Shows

A review of published research found that AGIs can produce modest improvements in blood sugar control when used alongside insulin. Specifically, the evidence suggests that AGIs may:

• Produce small reductions in HbA1c (a measure of average blood sugar over three months)

• Improve blood sugar control after meals

• Potentially lower the total amount of insulin some people need

These benefits are real but modest—AGIs are not a game-changer for blood sugar management, but rather one tool that may help certain individuals.

The Gastrointestinal Challenge

The main barrier to using AGIs is gastrointestinal side effects. Because AGIs slow carbohydrate digestion, undigested carbohydrates pass into the lower digestive tract, where bacteria ferment them. This causes bloating, gas, and other digestive discomfort.

These side effects are a significant limitation. Many people stop taking AGIs because the digestive problems outweigh the modest blood sugar benefits. Researchers recognize this as a major reason why AGIs have not become widely used in Type 1 diabetes treatment.

Who Might Benefit Most, and How AGIs Compare to Other Options

AGIs may be most useful for people who experience large blood sugar spikes after eating, consume diets high in carbohydrates, or cannot tolerate other adjunctive medications. They are particularly relevant for those whose blood sugar challenges are mainly driven by what happens after meals.

When compared to other medications used alongside insulin—such as metformin, pramlintide, GLP-1 agonists, DPP-4 inhibitors, and SGLT-2 inhibitors—newer therapies often offer broader benefits beyond post-meal glucose control. However, AGIs may still play a role for carefully selected individuals whose needs align with how these medications work.

Evidence label

Source: Mini reviews in medicinal chemistry. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.